Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2026-02-03

FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Mylan Institutional LLC)

View source ↗

Summary

FDA approved a supplemental application for Ibandronate Sodium submitted by Mylan Institutional LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IBANDRONATE SODIUM (ibandronate sodium)

Snippet

SUPPL AP for IBANDRONATE SODIUM (IBANDRONATE SODIUM)